Xcout Intel
ApoGlyx competitors & alternatives
The 12 closest competitors and alternatives to ApoGlyx among drug discovery companies — ranked by similarity to what ApoGlyx actually does, not by market-cap band.
Subscribe to see ApoGlyx’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About ApoGlyx
ApoGlyx is a Swedish life science company located in Lund that focuses on developing innovative medicines for acute systemic inflammatory diseases such as sepsis and acute pancreatitis.
ApoGlyx at a glance
ApoGlyx is a drug discovery company headquartered in Sweden. Its most recent funding round, Seed, raised $678,000 in October 2021. Xcout tracks 7 named people at ApoGlyx, including Michael Rützler (Chief Executive Officer).
ApoGlyx leadership
- Michael RützlerChief Executive Officer
- Preben Bruun-NyzellChairman of the board
- Søren NielsenCo-founder
- Andreas L. NorlinMember of the Board of Directors
- Anja HolmBoard Member
- Kenneth StokhomBoard Member
1 more named person on record for ApoGlyx, with roles, board committees and tenure — see the full roster →
ApoGlyx funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $678,000 | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 ApoGlyx competitors
Ranked by semantic similarity — how close each company is to ApoGlyx by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar drug discovery company
Gesynta Pharma AB is a pharmaceutical manufacturing company headquartered in Stockholm, Sweden, dedicated to developing innovative anti-inflammatory and pain-relieving therapies targeting the mPGES-1 enzyme.
Similar drug discovery company
Vivacelle Bio, Inc. is a Chicago-based developmental-stage biotechnology company pioneering innovative intravenous fluid therapies for treating conditions like sepsis and organ failure.
Similar drug discovery company
MinervaX is a privately held biotechnology company headquartered in Copenhagen, Denmark, pursuing the development of a novel maternal prophylactic vaccine for the prevention of Group B Streptococcus disease.
Similar drug discovery company
AnaCardio AB is a privately held Swedish clinical-stage biopharmaceutical company headquartered in Stockholm. The company focuses on developing novel drugs designed to treat heart failure.
Similar drug discovery company
NXI Therapeutics AG is a biotech company based in Basel, Switzerland, focused on researching and developing selective immunosuppressive drugs and immunotherapies for autoimmune diseases and transplantation.
Similar drug discovery company
Omniox, Inc. is an early-stage biopharmaceutical company located in San Francisco, California, focused on developing new medicines for hypoxic diseases.
Similar drug discovery company
Ahammune Biosciences is an India-based drug-discovery biotechnology company focused on developing small-molecule therapies for immune-mediated and inflammatory diseases. It serves pharmaceutical and healthcare markets by advancing novel immunomodulatory drug candidates toward clinical development.
Similar drug discovery company
Kinoxis Therapeutics Pty Ltd is an Australian-based, clinical-stage biotechnology company that develops first-in-class therapeutics targeting ALOX15 to address central nervous system (CNS) diseases.
Similar drug discovery company
Tacalyx is a life sciences and biotechnology company headquartered in Berlin, Germany, focused on developing lead TACA-targeted therapeutics.
Similar drug discovery company
Smartbax is a biotechnology startup founded in Munich, Germany, in 2021, dedicated to developing innovative next-generation antibiotics to combat the rising threat of multidrug-resistant bacteria.
Similar drug discovery company
Glycomine, Inc. is a biotherapeutics company focused on developing replacement therapies and treatments for serious rare genetic diseases, operating out of major life science hubs in San Francisco and Boston.
Similar drug discovery company
Salvina Therapeutics AG is a Swiss biotechnology research company that develops novel antibodies targeting TNF and TNF superfamily members to address inflammatory and autoimmune diseases. The privately held firm focuses on drug development approaches designed to improve safety and overcome efficacy barriers in these therapeutic areas.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of ApoGlyx and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for ApoGlyxand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →